Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00397930 · ClinicalTrials.gov registry record · Phase 2

Yoga in Treating Sleep Disturbance in Cancer Survivors

A Phase 2 study of Cancer and Fatigue, sponsored by Gary Morrow.

Completed
Registry status
Phase 2
Development phase
410
Enrollment target
11
Study locations

NCT00397930 is a Phase 2 study of Cancer and Fatigue that has completed, run by Gary Morrow. The registered enrollment target is 410 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (88% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00397930, a Phase 2 study of Cancer and Fatigue, has completed, sponsored by Gary Morrow.

COMPLETED
Registry status
Phase 2
Development phase
410 participants
Enrollment target
11
Study locations

Study Summary

RATIONALE: Yoga may help improve sleep, fatigue, and quality of life in cancer survivors. PURPOSE: This phase II trial is studying how well yoga works in treating sleep disturbance in cancer survivors.

Interventions

  • PROCEDURE Standard Care Control Condition
  • PROCEDURE Yoga Intervention (YOCAS)

Study Locations (11)

Michigan

  • CCOP - Grand Rapids - Grand Rapids
  • CCOP - Kalamazoo - Kalamazoo

Illinois

  • CCOP - Central Illinois - Decatur

Kansas

  • CCOP - Wichita - Wichita

Missouri

  • CCOP - Kansas City - Kansas City

New York

  • CCOP - Hematology-Oncology Associates of Central New York - East Syracuse

North Carolina

  • CCOP - Southeast Cancer Control Consortium - Goldsboro

Ohio

  • CCOP - Columbus - Columbus

Oregon

  • CCOP - Columbia River Oncology Program - Portland

Trial Details

FieldValue
Enrollment Target 410 participants
Start Date 2006-10
Est. Completion 2013-06
Phase Phase 2

Sponsor

Gary Morrow

16 total trials

What the Registry Record Tells You About NCT00397930

The ClinicalTrials.gov registry entry for NCT00397930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard Care Control Condition is the first listed.

NCT00397930 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Michigan, Illinois, Kansas.

Frequently Asked Questions

What is clinical trial NCT00397930 about?

NCT00397930 is a clinical study titled "Yoga in Treating Sleep Disturbance in Cancer Survivors". RATIONALE: Yoga may help improve sleep, fatigue, and quality of life in cancer survivors. PURPOSE: This phase II trial is studying how well yoga works in treating sleep disturbance in cancer survivors.

What is the current status of trial NCT00397930?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 410 participants. The study started on 2006-10. Estimated completion is 2013-06.

What conditions does trial NCT00397930 study?

This clinical trial studies the following conditions: Cancer, Fatigue, Sleep Disorders.

What interventions are being tested in trial NCT00397930?

The interventions under investigation include: Standard Care Control Condition (PROCEDURE), Yoga Intervention (YOCAS) (PROCEDURE).

Who is sponsoring clinical trial NCT00397930?

This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00397930 being conducted?

This trial has 11 study locations across Illinois, Kansas, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.